Treatment of refractory chronic inflammatory demyelinating polyneuropathy with interferon β1B [10]

Journal of Neurology

Volumn 252, Issue 11, 2005, Pages 1420-1422

  Cocco, Eleonora ^a   Mamusa, Elena ^a   Carboni, Nicola ^a   Marrosu, Giovanni ^a   Vannelli, Alessandro ^a   Mascia, Maria Giuseppina ^a   Sirca, Antonella ^a   Marrosu, Maria Giovanna ^a,b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b Binaghi Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; INTERFERON BETA SERINE;

ADULT; AUTOIMMUNE DISEASE; CASE REPORT; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL EXAMINATION; CLINICAL FEATURE; FEMALE; HUMAN; LETTER; MOTOR NERVE CONDUCTION; NEUROLOGIC EXAMINATION; PLASMAPHERESIS; PRIORITY JOURNAL; SENSORY NERVE CONDUCTION; THYROID DISEASE; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADULT; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INTERFERON-BETA; NEURAL CONDUCTION; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; THYROID DISEASES;

EID: 28144446975     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-005-0876-y     Document Type: Letter

References (14)

1. Hadden RD, Sharrack B, Bensa S, Soudain SE, Hughes RA (1999) Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 53:57-61
2. Hughes RA (2003) Management of chronic inflammatory demyelinating polyradiculoneuropathy. Drugs 63:275-287
3. Hughes R, Bensa S, Willison H, Van den Bergh P, Comi G, Illa I, Nobile-Orazio E, van Doom P, Dalakas M, Bojar M, Swan A; Inflammatory Neuropathy Cause and Treatment (INCAT) Group (2001) Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 50:195-201
4. IFNB Multiple Sclerosis Study Group (1993) Interferon beta 1b is effective in relapsing-remitting multiple sclerosis: I Clinical results of a multicenter, randomised, double-blind, placebo-controlled trial. Neurology 43:655-661
5. rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH, et al. (1996) Intramuscular interferon beta 1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285-294
6. Kleyweg RP, Van de Meche FGA, Schmitz PIM (1991) Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain Barré Syndrome. Muscle Nerve 14:1103-1109
7. Kuntzer T, Radziwill AJ, Lettry-Trouillat R, Naegeli C, Ochsner F, Erne B, Steck AJ, Bogousslavsky J (1999) Interferon-betala in chronic inflammatory demyelinating polyneuropathy. Neurology 53:1364-1365
8. Main M, Kairon H, Mercuri E, Muntoni F (2003) The Hammersmith Functional Motor Scale for Children with Spinal Muscular Atrophy: a Scale to Test Ability and Monitor Progress in Children with Limited Ambulation. Eur J Paediatr Neurol 7:155-159
9. van Doorn PA, Ruts L (2004) Treatment of chronic inflammatory demyelinating polyneuropathy. Curr Opin Neurol 17:607-613
10. Pirko I, Kuntz NL, Patterson M, et al. (2003) Contrasting effect of IFN beta and IVIg in children with central demyelination. Neurology 60:1697-1699
11. Ropper AH (2003) Current treatment for CIDP. Neurology 60(8):16-22
12. The PRISMS (Prevention of Relapses and Disability by Interferon beta 1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta 1a in relapsing-remitting multiple sclerosis. Lancet 352:1498-1504
13. Toyka KV, Gold R (2003) The pathogenesis of CIDP: Rationale for treatment with immunomodulatory agents. Neurology 60:2-7
14. Vallat JM, Hahn AF, Leger JM, Gros DP, Magy L, Tabaraud F, Bouche P, Preux PM (2003) Interferon beta-1a as an investigational treatment for CIDP. Neurology 60:23-28